| Name | Title | Contact Details |
|---|
GEC Packaging Technologies consists of the integrated business units of Graham Packaging, Evergreen Packaging and Closure Systems International. We employ over 14,000 team members and have 127 facilities in 35 countries. With a customer base of national and international brands, GEC Packaging Technologies companies supply a wide range of package formats to meet customer and consumer needs. Our portfolio of packaging technologies, along with our network of high-profile customers and suppliers, offers team members throughout our organization exceptional opportunities for personal and professional growth.
indiana metal craft inc is a Bloomington, IN-based company in the Manufacturing sector.
Bluffton Motor Works is a Bluffton, IN-based company in the Manufacturing sector.
Itw Industrial Finishing is a Glendale Heights, IL-based company in the Manufacturing sector.
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company`s lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe™. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the company is currently waiting for regulatory approval to begin the TAVVE first-in-human trial for enVVe.